Thiamine responsive megaloblastic anemia syndrome

Thiamine responsive megaloblastic anemia syndrome (also known as Rogers Syndrome) is a very rare autosomal recessive genetic disorder affecting a thiamine transporter, which is characterized by megaloblastic anemia, diabetes mellitus, and hearing loss. The condition is treated with high doses of thiamine (vitamin B1).

Thiamine responsive megaloblastic anemia syndrome
SpecialtyMedical genetics
ComplicationsDiabetes mellitus, anemia, hearing loss
CausesSLC19A2 gene mutation[1]
TreatmentThiamine

Signs and symptoms

In most cases (80-99%), people with this condition experience poor appetite (anorexia), diarrhea, headache, and lethargy.[1] Thiamine responsive megaloblastic anemia syndrome is associated with progressive sensorineural hearing loss. Additional manifestations include optic atrophy, short stature, enlarged liver, and an enlarged spleen.[2] Some cases may affect the heart, leading to abnormal heart rhythms.[3]

Treatment

Treatment consists of high doses of oral thiamine. Treatment can delay the onset of diabetes mellitus, and reverses anemia. If treatment is initiated early, thiamine deficiency can be prevented.

Genetics

The condition is inherited in an autosomal recessive fashion, and is caused by a mutation in the SLC19A2 gene.[1]

History

The condition was first described in 1969 by Dr. Lon E. Rogers, a pediatric hematologist in Dallas, Texas.

References
  1. "Thiamine responsive megaloblastic anemia syndrome". Genetic and Rare Diseases Information Center. National Center for Advancing Translational Science.
  2. Matthews, Lulu (February 17, 2009). "Thiamine Responsive Megaloblastic Anemia" (PDF). Indian Pediatrics. 46.
  3. "Thiamine-responsive megaloblastic anemia syndrome". Genetics Home Reference. US National Library of Medicine.
Classification
External resources
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.